Sanofi-Aventis Buys Chattem, a Leader in Over-the-Counter Sales

Sanofi-Aventis (SNY) announced Monday it will acquire Chattem Inc. (CHTT) for about $1.9 billion -- paying $93.50 per share, a 34% premium over Chattem's closing price Friday. The deal will create the world's fifth-largest consumer health-care company by revenues and helps the French drugmaker diversify into over-the-counter and consumer brands, a strategy used by Johnson & Johnson (JNJ), and one many pharmas seek to adopt before the coming patent cliff."Over-the-counter and consumer brands are core growth platforms identified in Sanofi-Aventis's broader strategy for achieving sustainable growth," the Paris-based Sanofi said in a statement. The tender offer will start in January, and the companies anticipate a first-quarter closing. Chattem's board of directors has unanimously approved the transaction.

Cracking the U.S. Market

%%DynaPub-Enhancement class="enhancement contentType-HTML Content fragmentId-1 payloadId-61603 alignment-right size-small"%% Sanofi-Aventis said it will maintain Chattem's two manufacturing facilities and will continue construction on a third, and will keep Chattem's corporate brand, with its senior execs leading the subsidiary.

Sanofi has generated $2 billion in OTC sales overseas this year, but buying Chattem -- a 130-year-old company based in Chattanooga, Tennessee -- will help it crack the U.S. market. That alone may be enough to justify spending four times as much as Chattam's 2008 sales: The U.S. represents about 25% of the worldwide market, Sanofi said, with more than $21 billion in sales last year.

Sanofi expects to expand sales of Chattem brands -- including Gold Bond skin products, Icy Hot muscle pain relief, and Selsun Blue dandruff shampoo -- into emerging markets and other regions where it has a strong presence. Chattem's growth of sales and profit has been sustainable, Sanofi said, with a compound annual growth rate of 12% in the past five years.

Allegra to Go Over-the-Counter?

Sanofi also wants to turn its prescription medication Allegra into an OTC product and plans to convert other drugs in time, a strategy increasing in popularity as pharmas try to maintain revenues of drugs going off patent. Sanofi said on Monday that it would stop development on two products: an investigational insomnia treatment, eplivanserin, and an atrial fibrillation, idrabiotaparinux.

The Food and Drug Administration has granted a fast-track designation for Sanofi's prostate-cancer drug, cabazitaxel, and the company is making progress with European regulators. Europe has recommended Sanofi's DuoPlavin combination of the Plavix blood-thinner and aspirin for patients taking both medicines to prevent clots.

While analysts at Jefferies & Co. said the updates result in the loss of 1% of estimated 2015 revenue, others generally approved of the deal with Chattem. Shares of Sanofi traded about 0.5% higher by noon, while CHTT shares rallied by more than 32%.
Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.